James N. Lowder
Keine laufenden Positionen mehr
Profil
James N.
Lowder worked as a Medical Director and Vice President in various pharmaceutical companies such as Becton, Dickinson & Co., Chimeric Therapies, Inc., PDL BioPharma, Inc., and Pharmacyclics LLC.
He also worked as a Senior Director in Dynavax Technologies Corp.
Lowder received his undergraduate and doctorate degrees from Case Western Reserve University.
Ehemalige bekannte Positionen von James N. Lowder
| Unternehmen | Position | Ende |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01.06.2008 |
| PDL BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 01.10.2006 |
| Chimeric Therapies, Inc. | Chief Tech/Sci/R&D Officer | 01.01.2002 |
| BECTON, DICKINSON AND COMPANY | Corporate Officer/Principal | 01.01.1998 |
| PHARMACYCLICS, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von James N. Lowder
| Case Western Reserve University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BECTON, DICKINSON AND COMPANY | Health Technology |
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
| Chimeric Therapies, Inc. |
